Current opinion in allergy and clinical immunologyHumansAsthmaSinusitisChronic DiseaseNasal Polyps
Depemokimab: a new long-acting anti-IL5 treatment for severe asthma and chronic rhinosinusitis with nasal polyps.
David I Bernstein
Published: 202510.1097/ACI.0000000000001112
Abstract
PURPOSE OF REVIEW: Clinical data are reviewed pertaining to depemokimab, the first extended life anti-IL5 mAb, for treating severe eosinophilic asthma. This molecule was engineered through amino acid modification (YTE mutation) of the Fc region. This…
Preview only. Read the full abstract at the source